Jci_page_head_homepage_01 Jci_page_head_homepage_02
Caroline Cheng, Dennie Tempel, Rien van Haperen, Hetty C. de Boer, Dolf Segers, Martin Huisman, Anton Jan van Zonneveld, Pieter J.M. Leenen, Anton van der Steen, Patrick W. Serruys, Rini de Crom, Rob Krams
Published in Volume 117, Issue 3
J Clin Invest. 2007; 117(3):616–626 doi:10.1172/JCI28180
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 8
The effect of fractalkine inhibition on T cells (A) and mast cells infiltration (B) and IL-6 and c-reactive protein (CRP) expression (C) in the LSS and OSS lesions.

Left panels: representative cross-sections taken from the LSS lesions from apoE–/– mice 9 weeks after cast placement with administration of rabbit IgG control antibodies or with the neutralizing antibody against fractalkine. Cross-sections were stained for CD3+ T cells (A) and mast cells using toluidine blue (B) (original magnification, ×200). CD3+ T cells and mast cells are indicated by arrows. Asterisks indicate the intimal area. Right panels: The number of positive cells counted in the intima (CD3+ T cells) and adventitia (mast cells) in the LSS and OSS lesions, with administration of rabbit IgG control antibodies or with the neutralizing antibody against fractalkine. n = 6. *P < 0.05 versus control antibody group. (C) Expression levels of CRP and IL-6 in carotid arteries at 9 weeks after cast placement in mice on a Western diet in response to fractalkine inhibition. Expression profiles were measured by QPCR using amplified RNA samples (10 animals per pool; n = 3). In the control antibody group, IL-6 and CRP levels in the LSS region were significantly upregulated versus the control and OSS regions. *P < 0.05 versus anti-fractalkine antibody group.